1502P - First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort
| Autor: | Amrane, K. 1, Geier, M. 1, Corre, R. 2, Léveiller, G. 3, Florence, G. 4, Lamy, R. 5, Bizec, J.L. 6, Goarant, E. 7, Robinet, G. 8, Ulrike, S. 9, Quere, G. 1, Bernier, C. 10, Descourt, R. 1 |
|---|---|
| Zdroj: | In Annals of Oncology October 2019 30 Supplement 5:v617-v617 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|